SAN FRANCISCO, Jan. 3, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. ((“Olema”, “Olema Oncology”, NASDAQ:OLMA) announced today that Sean Bohen, MD, President and Chief Executive Officer, at the 41stSt Annual JP Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 2:15 p.m. PT (5:15 p.m. ET).
A live webcast of the presentation and all accompanying presentation materials will be available on the News & Events section of Olema’s Investor Relations website at www.olema.com. The webcast will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for cancer in women. Olema’s lead product candidate, OP-1250, is a proprietary, orally available small molecule with dual activity as a total estrogen receptor (ER) antagonist (CERAN) and as a selective ER degrader (SERD). It is currently being tested both as a single agent in an ongoing Phase 2 clinical trial and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib) in patients with recurrent, locally advanced, or metastatic ER evaluates -positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted Fast Track Designation by the FDA. Olema is headquartered in San Francisco with offices in Cambridge, Massachusetts.
IR contact:
Courtney Dugan, Vice President, Investor Relations and Communications
ir@olema.com
media contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com
[ad_2]
Source story
